Citrine Medicine Secures $80 Million Series A Financing to Advance Rare Disease Ecosystem in China

Langhua Pharma, a Chinese pharmaceutical company focused on the field of rare diseases, announced todayBu, the company completed8000 $10,000A round of financing. This round was led by Spring Capital, an investment institution in the Chinese healthcare sector, with participation from 3H Health Investment and Wu Capital. The three founding institutional investors, F-Prime Capital,F-Prime Capital He WeiwuCapital continues to pour in. As a rare disease treatment platform, Langhua Pharma is committed to introducing rare disease drugs to the Chinese market,Establish China’s first rare disease ecosystem to support tens of millions of Chinese patients with rare diseases in urgent need.

China’s rare disease drug market holds immense potential but remains largely untapped. It is estimated that there are over 20 million patients with rare diseases in China, yet they currently face significant challenges in diagnosis, treatment, and insurance coverage.

Since its founding in 2019, Langhua Pharmaceuticals has assembled a first-class team of senior management and experts, with members boasting decades of experience in rare diseases and China’s healthcare industry.

Ms. Lin Rui, Partner at Sidao Capital and Board Member of Langhua Pharmaceuticals, stated: “Langhua is committed to introducing safe and effective therapies for rare diseases to patients in China. Our goal is to establish a patient-centric ecosystem for rare diseases by collaborating with various stakeholders to fundamentally address issues of drug accessibility and affordability.”

In recent years, Chinese regulatory authorities have introduced multiple policy measures to encourage the introduction, research and development, and production of drugs for rare diseases, while accelerating the registration, review, and approval processes for these medications. Currently, clinical trial data obtained overseas for specific rare disease drugs can be directly submitted for use in the approval process in China. Langhua Pharma will focus on validated drugs and assist in accelerating the global development of pharmaceutical products.

Dr. Dandan Dong, Managing Director at Wu Capital, stated, “Wu Capital’s mission and vision are to invest in companies that improve the quality of life for patients worldwide. Our co-founding investment in Langhua is a natural extension of this belief, as we recognize the significant unmet needs of patients with rare diseases. We are delighted to partner with Langhua and look forward to jointly delivering innovative therapies to patients with rare diseases.”

Ms. Lin Rui added, “Steadview Capital has achieved remarkable success in startup incubation. Over the past decade, we have actively built a comprehensive healthcare ecosystem in China, spanning new drug R&D, medical devices, healthcare services, and digital solutions. Langhua Pharmaceuticals possesses unique advantages that enable it to fully leverage the resources of all its investors, including the resource network of Steadview Capital’s global platform, thereby benefiting from the synergies of this extensive network. We believe Langhua can deliver substantial benefits to the rare disease patient community.”

Dr. Chong Xu, Executive Director at F-Prime Capital, stated, “F-Prime Capital actively supports and makes long-term investments in companies developing therapies for rare diseases. We participated in the founding of Langhua Pharmaceuticals because we believe the company has the potential to significantly improve the lives of patients with rare diseases in China and their families. We warmly welcome new investors to join us in collaborating to support Langhua Pharmaceuticals in fulfilling its critical mission: providing important therapeutic options for rare diseases to Chinese patients, while accelerating the development of rare disease drugs on a broader scale.”

Dr. Wu Hui, Managing Director at Quanchuang Capital, stated, “We are honored to lead this Series A financing round and join hands with Langhua’s founding investors to provide life-changing innovative therapies for patients with rare diseases in China. Quanchuang Capital remains committed to delivering new solutions to patients and addressing their unmet medical needs. We look forward to providing strong support to Langhua’s capabilities and pipeline in talent acquisition, local operational resources, and overseas product collaborations. With robust support from our investor base, we are confident that Langhua will emerge as a leader in the field, accelerating the development of innovative drugs for rare diseases both in China and globally.”

Dr. Wang Minchuan, Partner at 3H Health Investment, stated, “We are delighted to participate in this financing round and, together with Langhua’s founding investors and Quanchuang Capital, to advance the development of rare disease care in China by providing world-class treatment solutions and innovative medicines to Chinese patients with rare diseases. We look forward to offering full support in the localization and industrialization of overseas products in China, helping Langhua become a leading enterprise in China’s rare disease sector.”

Langhua Pharmaceuticals is a China-based pharmaceutical company focused on the treatment of rare diseases. Co-founded by Vertex Ventures, F-Prime Capital, and Wu Capital, the company is dedicated to providing clinically validated therapies to patients with rare diseases.

Langhua Pharma leverages internet tools and big data analytics to establish a patient-centric service platform for the entire rare disease community, aiming to raise public awareness of rare diseases, support screening and diagnosis for physicians and patients, and facilitate comprehensive disease management.

Fidelity International Limited (FIL) is a global proprietary investment institution backed by the Fidelity Group. Leveraging its unique capital attributes, FIL can flexibly deploy funds to support innovative enterprises in disrupting or leading markets, helping entrepreneurs achieve their ambitions. Currently, FIL, together with affiliated funds under the Fidelity Group, ranks among the top ten globally in venture capital. Our global ecosystem continuously provides portfolio companies with a vast talent pool and deep local knowledge to support their business development.

With over 20 years of venture capital experience in China, Shidao has invested in more than 100 companies in the healthcare and technological innovation sectors. Over the past decade, we have invested nearly $6 billion in startups worldwide.

F-Prime Capital is a global venture capital firm focused on the life sciences, healthcare, and technology sectors. Since 1969, F-Prime has worked closely with entrepreneurs and academics to deliver innovative solutions to some of the most significant challenges in healthcare and technology worldwide. For more information, please visit www.fprimecapital.com.

Quanchuang Capital is a venture capital fund focused on early-stage and growth-stage companies in the life sciences sector. Driven by innovation and guided by unique scientific and commercial insights, we identify, build, and invest in leading life science enterprises with high-growth potential worldwide. Our portfolio includes companies developing cutting-edge innovative therapies, advanced technology platforms, and industry leaders that fill critical gaps in the ecosystem.

Quanchuang Capital currently maintains offices in Shanghai, San Francisco, and Boston. Leveraging our extensive industry experience and deep sector resources, our professional investment team identifies and incubates the next generation of outstanding companies. We are committed to providing robust support for the strategy, operations, and development of emerging pharmaceutical and healthcare technology enterprises, assisting companies at various stages of growth with their transformations on a global scale, and helping them maximize their value.

3H Health Investment is a private equity fund dedicated to investing in the health industry. We invest in innovative technologies within the medical field, driving their clinical translation and industrialization to save more lives while improving patients’ quality of life. Leveraging our extensive resources in clinical practice, industry, and policy, 3H collaborates with partners to build great health technology enterprises.

Wu Capital is a Chinese family wealth management firm founded in 2013. As a representative of evergreen funds, Wu Capital is committed to identifying outstanding investors and entrepreneurs worldwide, leveraging its deep-rooted industrial resources and expertise in China to foster the growth of its portfolio companies. Focusing on new products, services, and experiences driven by technological advancements and shifting paradigms, Wu Capital strives to be the most patient and steadfast supporter and companion to entrepreneurs, embracing a global perspective while achieving mutual success.